LanzaTech (LNZA) said Tuesday it plans to spin out its synthetic biology unit LanzaX through a partnership with Tharsis Capital to prioritize its primary biorefining operations.
The spin-out will transfer more than 30 employees and existing contracts to LanzaX, aiming to reduce LanzaTech's annual costs by $8 million, the company said.
Timing of the move was described as "in the coming months."
LanzaTech added Tharsis Capital will support LanzaX in securing investments for its pipeline, which includes biochemicals and specialty products.
The company said it appointed Justin Pugh as interim CFO, succeeding Geoff Trukenbrod, effective immediately, who previously worked for FTI Capital Advisors in the same capacity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。